Novocure and Cyclacel Pharmaceuticals Surge on Positive FDA Trial News

NEW YORK, NY / ACCESSWIRE / April 4, 2017 / Both companies saw double digit percentage gains Monday as FDA testing returned positive Phase II and Phase III endpoints. Both biotech companies are engaged in developing cancer fighting drugs.

RDI Initiates
Coverage:

Novocure Ltd. https://ub.rdinvesting.com/news/?ticker=NVCR

Cyclacel
Pharmaceuticals Inc. https://ub.rdinvesting.com/news/?ticker=CYCC

Novocure advanced 37.04% to close at $11.10 on Monday. The stock traded between $11.00 and $14.30 on volume of 23.5 million shares traded. The company announced its Phase III FDA trial results in combining Optune with the standard of-care chemotherapy, Temozolomide. The data shows improvement in overall survival rates at two, three and five year for newly diagnosed patients with brain cancer. A total of 695 patients were included in the EF-14 FDA trial, and were followed up for a median of 40 months, with patients surviving in a range between 2 and 5 years.

Access RDI’s Novocure Research Report at: https://ub.rdinvesting.com/news/?ticker=NVCR

Cyclacel Pharmaceuticals advanced 74.46% to close at $6.42 on Monday. The stock traded between $4.12 and $6.59 on volume of 12.9 million shares traded. The company presented data at the American Association for Cancer Research Annual Meeting in Washington, D.C. that showed its 2nd generation CDK2/9 Inhibitor, CYC065, causes marked antineoplastic effects by engaging anti-metastatic pathways, increasing positive outcomes for lung cancer patients. Investors were excited by the news as there are many potential applications for the therapy should it be approved for commercial use.

The company also announced its 4th quarter and full year financials for the year ending December 31, 2016. Cyclacel had revenues of $0.3 million with operating expenses of $3.45 million for the quarter ending December 31, 2016.

Access RDI’s Cyclacel Pharmaceuticals Research Report at:
https://ub.rdinvesting.com/news/?ticker=CYCC

Our Actionable Research on Novocure Ltd. (NASDAQ: NVCR) and Cyclacel Pharmaceuticals Inc. (NASDAQ: CYCC) can be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and reviewed by Nadia Noorani, CFA® charter holder. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com

ReleaseID: 458931